



## **Carotid and femoral atherosclerotic plaques show different morphology.**

Fanny Herisson, Marie-Françoise Heymann, Maud Chétiveaux, Céline Charrier, Séverine Battaglia, Paul Pilet, Thierry Rouillon, Michel Krempf, Patricia Lemarchand, Dominique Heymann, et al.

### ► **To cite this version:**

Fanny Herisson, Marie-Françoise Heymann, Maud Chétiveaux, Céline Charrier, Séverine Battaglia, et al.. Carotid and femoral atherosclerotic plaques show different morphology.: Patterns of Peripheral Arterial Disease. *Atherosclerosis*, Elsevier, 2011, 216 (2), pp.348-54. <10.1016/j.atherosclerosis.2011.02.004>. <inserm-00642808>

**HAL Id: inserm-00642808**

**<http://www.hal.inserm.fr/inserm-00642808>**

Submitted on 18 Nov 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Regular article**

**Carotid And Femoral Atherosclerotic Plaques Show Different Morphology**

Short title: Patterns of Peripheral Arterial Disease

Fanny Herisson, Marie-Françoise Heymann, Maud Chétiveaux, Céline Charrier,  
Séverine Battaglia, Paul Pilet, Thierry Rouillon, Michel Krempf, Patricia Lemarchand,  
Dominique Heymann and Yann Gouëffic.

*FH and MFH contributed equally to this work.*

INSERM, U957, Nantes, F-44000 France (FH, MFH, DH, CC, SB)

Université de Nantes, Nantes, F-44000 France (FH, MFH, CC, MC, SB, PP, TR, MK,  
PL, DH, YG)

CHU de Nantes, Service de neurologie, Nantes, F-44000 France (FH)

CHU Nantes, Service d'anatomopathologie, Nantes, F-44000 France (MFH)

INSERM U791, F-44000 France (PP, TR)

CHU Nantes, l'institut du thorax, Service d'endocrinologie, Nantes, F-44000  
France (MK)

INSERM, U915, Nantes, F-44000 France (MC, MK, PL, YG)

CHU Nantes, l'institut du thorax, Centre d'investigation clinique, Nantes, F-44000  
France (PL, YG)

CHU Nantes, l'institut du thorax, Service de chirurgie vasculaire, Nantes, F-44000  
France (YG)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Correspondence to:**

Yann Gouëffic, MD, PhD

Department of Vascular Surgery, Institut du Thorax

Hôpital Guillaume et René Laënnec, Bd J. Monod St Herblain, 44093 Nantes Cedex

1, France

Phone: +33 2 40 16 50 93

Fax: +33 2 40 16 50 81

E mail: [yann.goueffic@chu-nantes.fr](mailto:yann.goueffic@chu-nantes.fr)

**Funding sources**

This study was supported by grant from La Fondation de L'Avenir (ET7-477).

Total number of pages: 26

Total words count: 5292, included :

- Abstract :176
- Manuscript : 3566
- Figure legends :231
- Tables : 238
- References : 1081

Total number of figures and tables: 7

## Abstract

**Objective**— Results of endovascular repair vary according to the arterial bed. We hypothesized that these differences may be related to the plaque features. To explore this hypothesis, we designed a prospective study that compared carotid and femoral atheroma.

**Methods and Results**— Patients that underwent femoral or carotid endarterectomy were included in our study. Demographic data and blood sampling were obtained prior to surgery. Plaques were evaluated for AHA grading, calcification and lipid content. Eighty eight plaques were harvested during this study (45 carotid specimens and 43 femoral specimens). No differences were noted between carotid and femoral groups regarding demographic and biological data. Histological data more frequently showed fibrous cap atheroma in carotid arteries (75%) and fibrocalcific plaques in femoral arteries (93%),  $p < 0.001$ . Morphological analyses showed a high prevalence of osteoid metaplasia in femoral arteries (63 %) compared to carotid arteries (20%,  $p < 0.001$ ). Biochemical analyses were consistent with histological data, showing higher calcium and lesser cholesterol concentrations in femoral than in carotid plaques ( $p < 0.01$ ).

**Conclusions**— Femoral and carotid plaques showed different morphology in comparable groups of patients.

**Keys words:** peripheral artery disease, atherosclerosis, vascular calcification, lipids

## Introduction

1  
2  
3 The definition of peripheral arterial disease (PAD) broadens towards a diverse  
4 group of disorders that lead to narrowing of supra-aortic trunks, aorta, upper and  
5 lower extremities arteries, and visceral arteries. PAD is a highly prevalent public  
6 health problem and is related to atherosclerosis. PAD has been classified as a  
7 coronary artery disease equivalent, meaning that patients with a diagnosis of PAD  
8 carry a risk for major coronary events equal to established coronary artery disease.<sup>1</sup>  
9  
10 Given the high prevalence of coronary disease, research has focused for a long time  
11 on coronary arteries and little is known about the specificities of PAD.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Currently, more and more studies show different results after endovascular treatment  
24 of PAD according to the arterial bed. For instance, in-stent restenosis rates differ  
25 according to the arterial bed. In-stent restenosis following carotid stenting is reported  
26 to occur in less than 10% of cases<sup>2</sup>, whereas it occurs in up to 40% of superficial  
27 femoral artery cases.<sup>3</sup> In-stent restenosis following coronary stenting is reported to be  
28 in the range of 10% to 15%.<sup>4</sup> However, stenting of lower extremities arteries is not as  
29 effective as stenting of coronary arteries since high rates of restenosis are observed  
30 in the range of 30% to 50%.<sup>5</sup> Moreover, the efficacy of drug eluting stents (DES)  
31 differs according to the arterial bed. In 2001, Morice et al. reported 0% of coronary in-  
32 stent restenosis at 9 months.<sup>6</sup> For peripheral arteries, DES have not shown to  
33 decrease in-stent restenosis in comparison to bare metal stents.<sup>7</sup>  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Even if numerous factors such as the haemodynamic factors, the length of the lesion,  
52 the run-off could alter the restenosis rate, some studies have shown that the nature  
53 of the atheromatous plaque could be also a crucial factor of in-stent restenosis.<sup>8, 9</sup>  
54  
55

56 For example, different studies have observed by intravascular ultrasound that soft  
57  
58  
59  
60  
61  
62  
63  
64  
65

atheromatous plaques are associated with a higher risk of in-stent restenosis.<sup>10</sup>

1  
2 However, these studies did not identify the components of the plaque. Few studies  
3  
4 have characterized atheromatous plaques according to the arterial bed. Some  
5  
6 studies used non-invasive arterial assessment to evaluate calcification according to  
7  
8 the arterial bed. CT scan for arterial calcium assessment is a non-invasive way of  
9  
10 obtaining information about the presence, location and extent of calcified plaques in  
11  
12 the arteries.<sup>11, 12</sup> These studies have shown that calcification increases in older  
13  
14 patients and varies according to each arterial bed. Furthermore, histopathological  
15  
16 studies have noted the presence of osteoid metaplasia in a range of 9% to 13% of  
17  
18 carotid plaques.<sup>13</sup>  
19  
20  
21  
22  
23  
24

25 To our knowledge, no previous study has compared advanced atherosclerotic lesions  
26  
27 between different types of peripheral arteries. This study was designed to test the  
28  
29 hypothesis of the existence of heterogeneity of atheroma expression among  
30  
31 peripheral arteries such as carotid and femoral arteries.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Materials and methods**

### **Patients**

From February 2008 to June 2009, atheromatous plaques were harvested from patients undergoing carotid or femoral endarterectomy at the department of vascular surgery of the Nantes University Hospital. Patients suffering from non-atherosclerotic peripheral arterial disease, thrombosis or restenosis, and patients who could not give their written consent were excluded. Demographic and clinical data were collected, including age, gender, treatment, cardiovascular risk factors, the presence of coronary artery disease or renal failure was documented. Prior to surgery, blood specimens were collected for lipid balance and phospho-calcic metabolism. Sample collection and handling was performed in accordance with the guidelines of the Medical and Ethical Committee in Nantes, France, and a written informed consent was requested for each patient.

### **Tissue sampling**

Endarteriectomies were performed on a consecutive series of patients using conventional surgical techniques. The plaque was removed at the bifurcation from within the lumen as a single specimen. All plaques were divided into 4 equal parallel sections. One part was processed for histological analysis, one section for scanning electron microscopy, and the last sections for lipid and calcium quantitative measurements.

### **Histology processing**

Atherosclerotic plaques were immediately fixed in 10% formalin overnight and decalcified in Sakura TDE 30 fluid during 24 hours. They were embedded in paraffin.



1 Sections (4µm thickness) were stained with hematoxylin eosin (HE) added with  
2 safran. Lipid staining was obtained with Oil Red O for esterified lipids and filipin  
3  
4 (filipin complex, F9765, Sigma-Aldrich, Poole, UK) for non-esterified lipids on frozen  
5  
6 sections of 4µm as described by Kruth.<sup>14</sup>  
7  
8  
9

## 10 **Histological grade of the atherosclerotic plaque**

11 The sections were graded according to a slightly modified AHA classification.<sup>15</sup>  
12

13 Modified AHA classification is based on the 9 categories, of which 6 correspond to  
14  
15 atheromatous plaques, type IX specimen (occlusion) were excluded from the study.  
16  
17

18 Briefly these categories include fibrous cap atheroma (type IV), fibrous cap atheroma  
19  
20 associated with fibrosis (type V), fibrocalcific plaque with more than 50% of plaque  
21  
22 area calcified (type VII), fibrocalcific plaque that is mainly fibrous without a lipid core  
23  
24 (type VIII). Complicated plaques (type VI) weren't taken into account since we were  
25  
26 interested by rating the underlying plaque.<sup>15, 16</sup> Inflammatory status of the plaque  
27  
28 was determined semi quantitatively by the average number of macrophages stained  
29  
30 by CD68 per mm<sup>2</sup> in the most representative part of the plaque and the percentage of  
31  
32 CD68 stained area within the entire plaque.  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **Immunocytochemistry**

42 Immunohistochemistry was performed on adjacent deparaffinized sections. Sections  
43  
44 were incubated with 3% hydrogen peroxide to block endogenous peroxidase and the  
45  
46 non specific bindings were blocked in 4% bovine serum albumin. Monoclonal  
47  
48 antibodies directed against (1) CD68, a marker of macrophages (dilution 1/60; 2165  
49  
50 Immunotech, Marseille France); (2) CD31, a marker of endothelial cells (dilution 1/20;  
51  
52 M823, Dako Ltd, Ely, UK); (3) smooth muscle-actin (prediluted, A2547, Sigma-Aldrich,  
53  
54 Saint-Quentin Fallavier, France). Biotinylated polyclonal anti-mouse secondary  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 antibody and peroxidase-conjugated streptavidin were applied for 1 hour each with  
2 the use of the extravidine peroxidase for 30 min and then revealed with an AEC  
3 staining kit (Sigma Aldrich). Preparations were counterstained with HE. A negative  
4 control was analyzed using a similar procedure excluding the primary antibody.  
5  
6  
7  
8  
9

### 10 **Quantitative measurements of calcium and lipids within the plaque**

11  
12  
13  
14  
15  
16  
17 Exact amounts of tissue samples, 30 to 50 mg each, were carefully weighted, 5- $\alpha$   
18 cholestane added for internal marker, homogenized with chloroform/methanol (2:1),  
19 and the homogenate was extracted two times with the mixture. The extract was  
20 evaporated and was saponified 1h at 70°C. Sterols were extracted with cyclohexane.  
21 After evaporation, sterol fractions were silylated. Cholesterol was quantitated with  
22 gas chromatography-mass spectrometry (GC-MS). The values are given as mg/g of  
23 tissue. For analysis of calcium, 50 samples were first dehydrated. After carbonization  
24 (550°C, 12 hours) ashes were dissolved in 1 ml of nitric acid and then 24 ml of 1%  
25 lanthanum oxide (LaCl<sub>3</sub>). Calcium absorbance was then determined by atomic  
26 absorption spectroscopy at 422.7 nm using a calcium lamp (Unicam Solaar 989  
27 Atomic Absorption Spectrometer, Cambridge, UK) and compared to a standard curve  
28 constructed using known dilutions of a solution of 1000  $\mu$ g/ml Ca in 1% LaCl<sub>3</sub>.  
29 Quantitative measurements were expressed in milligrams for gram of dried tissue.  
30 For some samples the length of the arterial segment available was not sufficient to  
31 perform all analyses, such specimens did not represent specific subgroup analysis.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Scanning electron microscopy (SEM)**

55  
56  
57 GMA-embedded plaques (10 carotid and 8 femoral specimens) were polished with  
58 graded silicon carbide grinding paper (Struers Denmark) and then gold-palladium-  
59  
60  
61  
62  
63  
64  
65

1 coated on a Desk III (Denton Vacuum, Moorestown, USA). SEM studies were  
2 performed with backscattered electrons (Leo 1450 VP, Zeiss, Oberkochen,  
3 Germany). Phospho-calcic ratios were determined by energy dispersive system X ray  
4 analysis (Inca Oxford instrument, UK).  
5  
6  
7  
8  
9

### 10 **Statistical analysis**

11  
12 Statistical analysis was performed using SPSS 10.0 software. Comparison of the  
13 data was assessed by either the Chi Square test or the two-sample Student's t-test.  
14 For phospho-calcic ratio analysis, non-parametric the Mann and Whitney test was  
15 used.  $P < 0.05$  was considered significant.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Results

### Baseline characteristics

Eighty eight patients were enrolled in the study; 45 underwent carotid endarterectomy (mean age  $69.7 \pm 1.65$  years, range 36-84) and 43 underwent femoral endarterectomy (mean age  $69.2 \pm 1.5$  years, range 59-85). In carotid endarterectomy specimens, 7 and 38 patients were respectively symptomatic and asymptomatic. The clinical presentation of symptomatic patients was detailed in table 1. A comparison of baseline clinical and biological preoperative data is shown in table 2. There was no significant difference between the two groups in terms of age, gender, cardiovascular risk factors, coronaropathy disease, renal failure, statins, antiplatelet therapies and vitamin K antagonists ( $p=NS$ ). Lipid and phosphocalcic parameters were similar in both groups of patients, regardless of vitamin D level, which was lower in patients with femoral endarterectomy ( $p<0.05$ ).

### ***AHA specimen classification***

The histological analysis according to AHA modified classification for human femoral and carotid plaques is shown in Figure 1. Seventy five percent of carotid plaques were classified as fibrous cap atheroma (types IV and V) *versus* 7% of the femoral plaques ( $p<0.001$ ). On the other hand, 93% of femoral plaques were classified as fibrocalcific plaques (types VII and VIII) *versus* 25% of carotid plaques ( $p<0.001$ ).

### ***Femoral and carotid plaques display different mineral patterns***

1  
2  
3 Sampling of human atherosclerotic plaques from patients undergoing carotid or  
4 femoral endarterectomy indicated the presence of 4 types of calcifications: sheetlike  
5 calcification, nodular calcification, clear centre calcification and osteoid metaplasia.  
6  
7 Sheetlike calcification was defined as a calcification front within fibrosis, surrounded  
8 by numerous calcified micronodules (Figure 2A and 2E). Nodular calcification was  
9 characterized by numerous stratified deposits of calcification with multinodular edges,  
10 consistent with an aggregation phenomenon, and the presence of very few cells  
11 (Figure 2B and 2F). Clear centre calcification consisted of vesicle- like structure  
12 outlined with calcium deposits (Figure 2C and 2G). The last type of calcification was  
13 osteoid metaplasia that consisted of mature bone with typical lamellar structure and  
14 often bone marrow (Figure 2D and 2H). The prevalence of each type of calcification  
15 was compared (Figure 3A). Femoral plaques exhibited significantly more sheetlike  
16 calcification (86% vs 62%;  $p < 0.05$ ) and nodular calcification (84% vs 58%,  $p < 0.01$ )  
17 when compared to carotid plaques. The clear centre calcification prevalence was  
18 similar between both specimen types. Femoral plaques more often displayed osteoid  
19 metaplasia (63% vs 20%  $p < 0.001$ ) when compared to carotid plaques. We noticed  
20 that osteoid metaplasia always developed in deep regions of the intimal layer, close  
21 to the media and vasa vasorum (data not shown). Histological analysis of sampling of  
22 femoral and carotid plaques did not indicate higher density of calcium in the outer  
23 part of the media. Twenty seven carotid specimens and 23 femoral specimens were  
24 analyzed to determine the calcium level within the plaque. Femoral plaques  
25 displayed significantly higher amounts of calcium ( $194 \pm 33$  mg/g vs  $85 \pm 16.2$  mg/g;  
26  $p < 0.01$ ) as compared to carotid plaques (Figure 3B). The phospho-calcic atomic ratio  
27 determined by SEM was similar in carotid ( $1.89 \pm 0.05$ ) and femoral plaques ( $1.85 \pm$   
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

0.34),  $p=0.11$ . These results are consistent with the presence of hydroxyapatite cristal.

CD31 and smooth muscle-actin immunostaining were not different between atherosclerotic plaques from patients undergoing carotid or femoral endarterectomy.

### ***Carotid plaques display more lipid and inflammation patterns than femoral plaques***

We observed intra- and extracellular lipid deposits within the plaque. Non esterified cholesterol was found within the macrophages (Figure 4 A). Results for quantitative analyses are shown in Figure 4B. Total cholesterol values differed significantly between carotid and femoral plaques. Mean cholesterol levels were higher in carotid plaques compared to femoral plaques ( $39.85 \pm 5.6$  mg/g vs.  $10.5 \pm 1.79$  mg/g;  $p < 0.001$ ). Concerning the distribution of inflammatory cells, twenty carotid and femoral specimen were analyzed. The mean total percentage of macrophage area was  $15.2 \pm 3.14\%$  within carotid plaques versus  $6.13 \pm 2.2\%$  within femoral plaques ( $p < 0.05$ ) (Figure 5A). Carotid plaques (figure 5C) showed a higher content of CD68 positive cells in relation to the total section area than femoral plaques (figure 5D):  $310.5 \pm 49.15$  versus  $174.5 \pm 39.75$  /  $\text{mm}^2$ ,  $p < 0.05$ , (Figure 5B).

## Discussion

1  
2  
3  
4  
5  
6  
7 In this study we have observed that, in comparable groups of patients, femoral and  
8  
9 carotid plaques showed different morphology. Indeed, carotid arteries displayed more  
10  
11 lipid and inflammatory content than femoral arteries while femoral arteries were more  
12  
13 prone to calcify and to develop osteoid metaplasia.  
14  
15

16  
17 Site specificity for atherosclerosis is largely described. Numerous factors could  
18  
19 influence regionally distinct atherosclerotic lesion development and therefore  
20  
21 morphology of atheromatous plaques. Site-selectivity of atherosclerotic lesions  
22  
23 includes differences in hemodynamics, the underlying wall structure, cardio-vascular  
24  
25 risk factors and cellular or biochemical parameters of the arterial wall. Site-specific  
26  
27 arterial wall structure could have a potential influence. However, carotid and femoral  
28  
29 artery bifurcations are both considered as a transitional zone between elastic and  
30  
31 muscular artery types without striking arterial geometry differences.<sup>17</sup> Regarding  
32  
33 blood flow patterns, this varies in different regions in quantitative detail and these  
34  
35 variations could have a complex effect on the development of atherosclerosis. For  
36  
37 example, peak/mean wall shear rates are higher in carotid arteries than in femoral  
38  
39 artery.<sup>18</sup> Blood flow variations may influence the relative residence time of  
40  
41 lipoproteins, blood borne molecules and inflammatory cells that come in contact with  
42  
43 the endothelial cells in each of these regions.<sup>19</sup> On the other hand, the hemodynamic  
44  
45 patterns may prime the gene expression profile of endothelial cells in subtle different  
46  
47 ways so that these cells react differently to cardiovascular risk factors.<sup>20</sup> Like  
48  
49 coronary artery lesions, PAD is influenced by cardio-vascular risk factors. For  
50  
51 instance, Baumgartner et al. have described a different distribution pattern of lower  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 limb atherosclerosis according to the cardiovascular risk factor profile of patients with  
2 peripheral arterial occlusive disease.<sup>21</sup> Risk factor profiles for each vascular territory  
3  
4 are different insofar as there is some evidence of a stronger association between  
5  
6 large vessel disease and smoking and dyslipidemia, whereas diabetes appears more  
7  
8 specific for small vessel disease. In their study, patterns of plaques were not  
9  
10 described. Different studies have already reported cellular or biochemical variations  
11  
12 in the arterial wall. To test the hypothesis of intrinsic differences in the artery wall,  
13  
14 Haimovici et al. used aortic homograft transplantation to examine the responses of  
15  
16 different aortic segments to a high fat atherogenic diet. Aortic segments in dogs from  
17  
18 atherosclerosis-resistant thoracic aorta were transplanted into atherosclerosis-  
19  
20 susceptible abdominal aorta and vice versa. After 1 year, the authors observed that  
21  
22 atherosclerosis-resistant segments transplanted into atherosclerosis-  
23  
24 susceptible abdominal aorta and vice versa. After 1 year, the authors observed that  
25  
26 atherosclerosis-resistant segments transplanted into atherosclerosis-prone positions  
27  
28 in the abdominal aorta remained lesion free even though abdominal aorta flanking  
29  
30 the transplanted thoracic segment developed severe aortic atherosclerosis. In the  
31  
32 same animals, atherosclerosis-prone segments transplanted into atherosclerosis-  
33  
34 resistant positions still developed severe aortic atherosclerosis even though the  
35  
36 flanking thoracic aorta was lesion-free.<sup>22</sup> The diversity of the origins of vascular cells  
37  
38 could provide explanations about how blood vessels differ from one another and why  
39  
40 they respond in disparate ways to common risk factors associated with vascular  
41  
42 disease. Indeed, Majesky emphasizes that smooth muscle cells arise from distinct  
43  
44 sources of progenitors, each with its own unique lineage and developmental history  
45  
46 and consequently participate to the vascular bed-specific patterns of  
47  
48 atherosclerosis.<sup>23</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 In the present study, the calcium content was higher in femoral plaques than in  
2 carotid plaques although the phospho-calcic atomic ratio was similar between both  
3 types of plaques. There is no evidence for higher prevalence of Monckeberg's  
4 disease in femoral versus carotid specimens in our study. Nevertheless,  
5 Mönckeberg's sclerosis is common in peripheral artery it could be difficult to  
6 distinguish Monckeberg's lesions from advanced atherosclerotic lesions.<sup>24</sup> CT scan  
7 for arterial calcium is a non-invasive tool for obtaining information about the  
8 presence, location and extent of calcified plaques in the arteries.<sup>11</sup> The findings on  
9 CT scans are expressed as a calcium score. These studies have shown that  
10 calcification varies according to each arterial bed. For example, calcium scoring was  
11 higher in iliac arteries than in carotid arteries. Differences in the content of calcium  
12 according to the arterial region is consistent with the histological grading that showed  
13 that femoral plaques are classified as fibrocalcific (VII and VIII types) whereas carotid  
14 plaques are classified as fibrous cap atheroma (IV and V types). In an autopsy study,  
15 Dalager et al. analyzed the coronary, carotid and superficial femoral arteries from  
16 100 individuals.<sup>15</sup> They clearly showed the artery related differences in phenotypic  
17 expression of atherosclerotic plaques. In the bifurcated carotid region most of the  
18 plaques were lipid core plaques (types IV and V) and more than half of femoral  
19 plaques were classified as fibrous type VIII lesions. In another autopsic study,  
20 Sawabe et al revealed that the severity of atherosclerosis differed among arteries.  
21 They observed that the aorta and arteries of the lower extremities were severely  
22 affected, while the abdominal arteries, such as the splenic and superior mesenteric  
23 arteries, were mildly affected.<sup>25</sup> Initiation and rate of lesion progression should be  
24 taken into account to interpret the histological grading related differences. Indeed our  
25 analysis is confined to a single point and assumes a similar rate of atheromatous  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 disease progression in each plaque location. Moreover, Stary showed that the  
2 natural trend of the plaque was toward a fibrocalcific phenotype.<sup>26</sup> According to  
3  
4 Dalager et al., carotid plaques seem to be observed sooner than femoral plaques  
5  
6 with a prevalence of lipid core plaques.<sup>15</sup> Consequently, these findings suggest the  
7  
8 hypothesis of different kinetics of progression of atheromatous plaques according to  
9  
10 the arterial region, however to date no data are available on this matter.  
11  
12

13  
14 Femoral plaques exhibit significantly more sheetlike calcification, nodular calcification  
15  
16 and osteoid metaplasia than carotid plaques. The most striking difference between  
17  
18 both types of plaques is related to the prevalence of osteoid metaplasia in femoral  
19  
20 plaques. Up to date, different studies reported the presence of both cartilaginous and  
21  
22 bone formation in atheromatous plaques but few studies reported prevalence of  
23  
24 osteoid metaplasia in peripheral arteries.<sup>13, 27, 28</sup> In carotid arteries, the prevalence of  
25  
26 ossification was evaluated approximatively between 9% to 13%.<sup>13, 28</sup> These data are  
27  
28 consistent with our own results. The origin of this pathological change has been  
29  
30 attributed to metaplastic osteogenesis along an endochondral pathway.<sup>29</sup> Although  
31  
32 we have punctually found cartilage tissue in our specimens (data not shown),  
33  
34 membranous ossification could not be excluded. In membranous ossification bone is  
35  
36 built via the differentiation of mesenchymal cells in osteoblasts that product osteoid  
37  
38 matrix that is further mineralized.  
39  
40  
41  
42  
43  
44  
45

46  
47 We observed a significant increase of the serum level of vitamin D in the patients  
48  
49 from the carotid group although all levels were clearly under normal values in both  
50  
51 groups. It is clear that vitamin D could influence PAD because of its effect on target  
52  
53 cells and tissues.<sup>30</sup> However, there is controversy concerning the action of vitamin D  
54  
55 on arterial calcification in humans. Even though vitamin D promotes calcifications in  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 vitro<sup>31</sup>, in clinical studies authors reported either no effect or an inverse relationship  
2 between vitamin D levels and vascular calcification.<sup>32-34</sup>  
3  
4

5 The present study is a cross-sectional study of carotid and femoral plaques obtained  
6 from different patients at a single point in time. Consequently, we cannot rule out a  
7 bias created by harvesting carotid and femoral plaques in different patients. Indeed,  
8 in order to obtain a better matching, carotid and femoral plaques should be harvested  
9 in the same patient. Obviously, few patients require both femoral and carotid  
10 endarterectomy at a single point in time. Although we can only postulate that the  
11 observed lesions represent the late plaque lesion, further studies of plaques are  
12 needed with a wide range of disease severity to further define plaque morphology,  
13 cellular and molecular factors involved in progression from the apparent early lesion  
14 to clinically significant artery stenosis. Furthermore, factors such as the delay  
15 between symptoms onset could influence plaque type. These factors differ between  
16 groups and could be a limit to this study. In carotid arteries, surgery is requested for  
17 different degree of stenosis according the symptomatology.<sup>35</sup> Moreover, in  
18 symptomatic carotids, it is recommended to undergo surgery in the 15 days following  
19 the onset of symptoms.<sup>35</sup> For femoral arteries, each patient underwent conservative  
20 therapy combined at least for 3 months before surgical procedure but the delay prior  
21 to surgery differs a lot between each patient according their clinical history.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 The results of this study demonstrate that femoral and carotid plaques show different  
48 morphology at a single point in time. Mechanisms and clinical implications of  
49 atheroma plaques heterogeneity within the arterial tree should be investigated for a  
50 better understanding of the characteristics of the arteries and to choose the best  
51 medical, endovascular or surgical option to treat atheromatous lesions.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Acknowledgments**

We thank Jean-Baptiste Michel, Béatrice Guyomarch, Alexandra Auvrignon, Karine Fajoles, Brigitte Hauraix and Stéphanie Crossouard for their excellent assistance. We also thank Marja Steenman for reviewing the English text of this manuscript.

## **Disclosures**

None

## References

1. Sabouret P, Cacoub P, Dallongeville J, Krempf M, Mas JL, Pinel JF, Priollet P, Steg G, Taminau D, Montalescot G; REACH Registry investigators. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. *Arch Cardiovasc Dis*. 2008;101(2):81-8.
2. Lal BK, Hobson RW 2nd, Goldstein J, Geohagan M, Chakhtoura E, Pappas PJ, Jamil Z, Haser PB, Varma S, Padberg FT, Cerveira JJ. In-stent recurrent stenosis after carotid artery stenting: life table analysis and clinical relevance. *J Vasc Surg*. 2003; 38(6):1162-8.
3. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery. *N Engl J Med*. 2006;354(18):1879-88.
4. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. *Circulation*. 2002; 106(22):2859-66.
5. Haider SN., Kavanagh EG., Forlee M, Colgan MP, Madhavan P, Moore DJ, Shanik GD. Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia. *J Vasc Surg*. 2006; 43(3):504-12.
6. Morice MC, Serruys P, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery

1 Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent  
2 for coronary revascularization. *N Engl J Med.* 2002; 346(23):1773-80.  
3  
4

5 7. Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. *J*  
6 *Endovasc Ther.* 2009; 16( Suppl 1):147-52.  
7  
8

9  
10 8. Endo A, Hirayama H, Yoshida O, Arakawa T, Akima T, Yamada T, Nanasato  
11 M. Arterial remodeling influences the development of intimal hyperplasia after stent  
12 implantation. *J Am Coll Cardiol.* 2001;37(1):70-5.  
13  
14  
15

16 9. Finet G, Weissman NJ, Mintz GS, Satler LF, Kent KM, Laird JR, Adelman  
17 GA, Ajani AE, Castagna MT, Rioufol G, Pichard AD. Mechanism of lumen  
18 enlargement with direct stenting versus predilatation stenting: influence of  
19 remodelling and plaque characteristics assessed by volumetric intracoronary  
20 ultrasound. *Heart.* 2003;89(1):84-90.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 10. Sahara M, Kirigaya H, Oikawa Y, Yajima J, Ogasawara K, Satoh H,  
32 Nagashima K, Hara H, Nakatsu Y, Aizawa T. Arterial remodeling patterns before  
33 intervention predict diffuse in-stent restenosis: an intravascular ultrasound study. *J*  
34 *Am Coll Cardiol.* 2003;42(10):1731-8.  
35  
36  
37  
38  
39  
40  
41

42 11. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano  
43 R. Quantification of coronary artery calcium using ultrafast computed tomography. *J*  
44 *Am Coll Cardiol.* 1990;15(4):827-32.  
45  
46  
47  
48  
49  
50

51 12. Allison MA, Criqui M, Wright CM. Patterns and Risk Factors for Systemic  
52 Calcified Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2004;24:331-6.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
13. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, Wolfe M, Neschis D, Milner R, Scoll B, Cusack A, Mohler ER 3rd. Bone formation in carotid plaques: a clinicopathological study. *Stroke*. 2002; 33(5):1214-9.
14. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. *Am J Pathol*. 1984; 114(2):201-8.
15. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. *Stroke*. 2007;38(10):2698-705.
16. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons From Sudden Coronary Death : A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. *Arterioscler Thromb Vasc Biol*. 2000(20):1262-75.
17. Janzen J. The microscopic transitional zone between elastic and muscular arteries. *Arch Mal Coeur Vaiss*. 2004;97(9):909-14.
18. Reneman RS, Arts T, Hoeks AP. Wall shear stress--an important determinant of endothelial cell function and structure--in the arterial system in vivo. Discrepancies with theory. *J Vasc Res*. 2006;43(3):251-69.
19. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. *Arterioscler Thromb Vasc Biol*. 2004; 24(1):12-22.
20. Hahn C, Swartz MA. Mechanotransduction in vascular physiology and atherogenesis. *Nat Rev Mol Cell Biol*. 2009; 10(1):53-62

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
21. Diehm N SA, Silvestro A, Do DD, Dick F, Schmidli J, Mahler F, Baumgartner I. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. *Eur J Vasc Endovasc Surg.* 2006; 31(1):59-63.
  22. Haimovici H, Maier N. Fate of aortic homografts in canine atherosclerosis. 3. study of fresh abdominal and thoracic aortic implants into thoracic aorta: role of tissue susceptibility in atherogenesis. *Arch Surg.* 1964; 89:961-9.
  23. Majesky MW. Developmental basis of vascular smooth muscle diversity. *Arterioscler Thromb Vasc Biol.* 2007; 27(6):1248-58.
  24. McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated Atherosclerotic Calcification and Moñckeberg's Sclerosis: A Continuum of Advanced Vascular Pathology in Chronic Kidney Disease. *Clin J Am Soc Nephrol.* 2008 ; 3: 1585–1598
  25. Sawabe M, Arai T, Kasahara I, Hamamatsu A, Esaki Y, Nakahara K, Harada K, Chida K, Yamanouchi H, Ozawa T, Takubo K, Murayama S, Tanaka N. Sustained progression and loss of the gender-related difference in atherosclerosis in the very old: a pathological study of 1074 consecutive autopsy cases. *Atherosclerosis.* 2006 186(2):374-9.
  26. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. *Arterioscler Thromb Vasc Biol.* 2000;20:1177–8.
  27. Qiao JH, Mertens RB, Fishbein MC, Geller SA . Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: morphologic evidence of enchondral ossification. *Hum Pathol.* 2003; 34(4):402-7.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
28. Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. *Virchows Arch.* 1998;433(6):559-65.
  29. Demer LL, Tintut Y. Vascular calcification : pathobiology of a multifaceted disease. *Circulation.* 2008;117:2938-48.
  30. Norman PE, Powell JT. Vitamin D, shedding light on the development of disease in peripheral arteries. *Arterioscler Thromb Vasc Biol.* 2005; 25(1):39-46.
  31. Hsu JJ, Tintut Y, Demer LL. Vitamin D and osteogenic differentiation in the artery wall. *Clin J Am Soc Nephrol.* 2008; 3(5):1542-7.
  32. Doherty TM, Tang W, Dascalos S, Watson KE, Demer LL, Shavelle RM, Detrano RC. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. *Circulation.* 1997; 96(5):1477-81.
  33. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Métivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. *J Am Soc Nephrol.* 2007; 18(2):613-20.
  34. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation.* 1997; 96(6):1755-60.
  35. Naylor AR, Rothwell PM, Bell PRF. Overview of the principal results and secondary analyses from the European and North American randomised trials of

endarterectomy for symptomatic carotid stenosis. Eur J Vasc Endovasc Surg. 2003 ;  
26(2):115-29.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure legends

**Figure 1 :** Histological classification of carotid and femoral plaques according to a slightly modified AHA classification (15). Type IV and V are defined as fibrous cap atheroma. Type VII and VIII are defined as fibrocalcific plaques.

**Figure 2:** Hematoxylin eosin and safran (HES) staining and scanning electron microscopy (SEM) backscattered electron images. (A) HES stain, original magnification X200 , sheetlike calcifications. (B) HES stain, original magnification X200, nodular calcifications. (C) HES stain, original magnification X400, clear centre calcifications. (D) HES stain, original magnification X100, osteoid metaplasia. (E) SEM, original magnification X 1000, sheetlike calcifications (F) SEM, original magnification X 500, nodular calcifications (G) SEM, original magnification X 1000, clear centre calcifications (H) SEM, original magnification X 250, osteoid metaplasia.

**Figure 3:** Qualitative (A) and quantitative (B, expressed as mean  $\pm$  SEM) assessments of mineral patterns in carotid and femoral plaques.\*P< 0.05, \*\*P< 0.01, \*\*\*P< 0.001

**Figure 4:** (A) Lipid staining was obtained with filipin and macrophages were stained by a monoclonal antibody directed against CD68. (B) Quantitative measurements of

cholesterol within carotid and femoral plaques were expressed in milligrams per gram  
± SEM of dried tissue. \*\*P<0.01

**Figure 5:** Quantitative measurements of macrophages within carotid and femoral  
arteries (A,B) \* P< 0.05. C : Example of CD68 staining of a carotid specimen,  
original magnification X50. D : Example of CD68 staining of a femoral specimen,  
original magnification X50.

Figure1




Figure 2






Figure 3







**Figure 4**



**Figure 5**





**Table 1:** Clinical presentation and delay to surgery of the seven symptomatic carotid patients.

SYMPTOMS	TYPE	DELAY TO SURGERY (days)
Hemiparesis	infarction	147
Aphasia and brachiofacial paresis	infarction	118
Brachiofacial paresis	infarction	58
Facial paresis	infarction	40
Amaurosis fugax	transient ischemic attack	120
Brachiofacial paresis	infarction	15
Aphasia and brachiofacial paresis	infarction	15

**Table 2:** Baseline characteristics, treatment and biomarkers according to atheromatous plaque location

	Carotid plaques (n=45)	Femoral plaques (n=43)	p
Demographic data and medical			
History*			
Age, y	69,7 (± 1.65)	69,2 (± 1.5)	0.8
Male, % (n)	71,1 (32)	86 (37)	0.12
Hypertension, % (n)	88.9 (40)	81.4 (35)	0.32
Diabetes, % (n)	17.8 (8)	20.9 (9)	0.71
Hypercholesterolaemia, % (n)	82.2 (37)	83.7 (36)	0.85
Smoking, % (n)	71.1 (32)	72.1 (31)	0.92
Body mass index, kg/m <sup>2</sup>	26.5 (± 0.7)	26.4 (± 0.6)	0.92
Coronaropathy, % (n)	55.6 (25)	53.5 (23)	0.85
Renal failure, % (n)	48.9 (22)	41.9 (18)	0.51
Medications*			
Statins, % (n)	84.4 (38)	76.7 (33)	0.36
Vitamin K antagonists, % (n)	2.2 (1)	4 (9.3)	0.15
Antiplatelet agents, % (n)	100 (45)	93 (40)	0.11

Biomarkers\*

LDL-C (g/L)	1 ( $\pm$ 0.05)	0.94 ( $\pm$ 0.05)	0.36
Vitamin D (ng/mL),	17.7 ( $\pm$ 1.58)	12,26 ( $\pm$ 1.06)	0.006
PTH (pg/mL)	51.96 ( $\pm$ 4,26)	54 ( $\pm$ 3.55)	0.71
Ionised calcium (mmol/L)	1.24 ( $\pm$ 0.01)	1.22 ( $\pm$ 0.01)	0.3

---

\*Clinical characteristics 'medications' and 'biomarkers' are expressed as mean $\pm$ SEM or % (n). LDL-C = low-density lipoprotein cholesterol